Conference Report | Rendu Biotech Shines at APASL 2025, Leading Innovations in Precision Diagnosis and Treatment of Liver Diseases

APASL

From March 26 to 30, 2025, the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) was held at the China National Convention Center in Beijing. Centered around the theme "Diverse Partnerships: Creating Miracles of Elimination and Cure", the conference brought together experts and scholars from over 50 countries to explore emerging trends in the diagnosis and treatment of liver diseases. HBV RNA, as a novel biomarker, became a key focus of attention.

Professor Jie Wang from the Center for Microbiology and Infectious Diseases at Peking University, Professor Jian Sun from Nanfang Hospital of Southern Medical University, Professor Zhenghong Yuan from Fudan University, and Professor Peter Revill from the Department of Infectious Diseases at the University of Melbourne, along with several other experts, presented thematic reports on HBV RNA. These covered fundamental research on its tissue distribution, correlations with other biomarkers, clinical significance, and potential application scenarios.

In addition, research teams from the Second Affiliated Hospital of Chongqing Medical University, Southwest Hospital of Army Medical University, the Second Hospital of Shandong University, and Xixi Hospital of Hangzhou also shared their findings related to HBV RNA at APASL.

These multi-dimensional presentations highlighted the pivotal role of Chinese research teams in advancing HBV RNA from a laboratory biomarker to a clinical diagnostic and therapeutic indicator. Their contributions not only underscore the strength of domestic innovation but also provide vital technical support for the global effort to cure hepatitis B.

As the first company in the world to obtain regulatory approval for an HBV RNA assay, Rendu Biotech showcased its core diagnostic solutions in the field of liver disease at the conference.

The fully automated, high-sensitivity quantitative HBV RNA assay drew significant attention for its patented direct quantification technology that resists interference, ensuring both high sensitivity and accuracy of results. Meanwhile, the fully automated, high-sensitivity HCV RNA assay attracted liver disease experts from around the world with its "sample-in, result-out" workflow and outstanding analytical performance.

Notably, Rendu Biotech is set to launch a high-sensitivity quantitative HBV DNA assay, further expanding its comprehensive product portfolio for full-cycle liver disease management.

As a representative of original molecular diagnostic innovation in China, Rendu continues to drive the standardization of liver disease diagnosis and treatment through innovation, contributing to the global effort to eliminate viral hepatitis.